Buscar
Mostrando ítems 1-3 de 3
Subcutaneous Tanezumab for Osteoarthritis: Is the Early Improvement in Pain and Function Meaningful and Sustained?
(Wiley, 2021-03-16)
[Abstract] Background: To evaluate if early improvements in pain and function with subcuta-neous tanezumab are meaningful and sustained over 24 weeks.
Methods: Patients with moderate- to- severe osteoarthritis (hip or ...
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
(BMJ, 2020-03-31)
[Abstract] Objective. Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up.
Methods. This double-blind, ...
Relationship Between Motion, Using the GaitSmartTM System, and Radiographic Knee Osteoarthritis: An Explorative Analysis in the IMI-APPROACH Cohort
(Oxford, 2020-12-25)
[Abstract] Objectives: To assess underlying domains measured by GaitSmartTMparameters and whether these are additional to established OA markers including patient reported outcome measures (PROMs) and radiographic parameters, ...